23andMe’s Evolution: From Genetic Testing to Comprehensive Health Care
Founded in 2006, 23andMe has undergone a remarkable journey. Despite its $6 billion valuation in 2021 when it went public, the company now faces the risk of being delisted from the Nasdaq as its stock continues to trade below $1 a share.
Navigating Challenges and Shifting Focus
CEO Anne Wojcicki has successfully steered 23andMe through various obstacles, including a 2013 order from the US Food and Drug Administration to halt the marketing of its health risk assessments until proper validation could be provided. Wojcicki reflects on this period:
There was the government shutdown in 2013. There were a number of things happening around data privacy. I think that also got people to pause.
During this time, 23andMe began to shift its focus from ancestry to health, aligning more closely with its ultimate vision.
Introducing Total Health: A Comprehensive Genomic Care Service
In November, 23andMe launched Total Health, a $1,200-a-year service that integrates genetic information into longitudinal care. By acquiring Lemonaid Health in 2021, the company aims to provide primary care founded on genomic medicine. Customers receive consultations with a clinical team, access to blood tests, and comprehensive genome analysis through exome sequencing.
Wojcicki envisions a future where genomic health care focused on prevention becomes the norm, with 23andMe owning virtual primary care based on genetic and biomarker data.
Targeting Proactive Health-Conscious Individuals
<p
5 Comments
Genetic testing companies walking a fine line between innovation and controversy.
The future of personalized medicine hinges on the success of companies like 23andMe
Founder’s hope for the future may be misplaced given the current scrutiny 23andMe faces.
With 23andMe under the microscope, will the founder’s optimism be enough to weather the storm
23andMe’s founder remains hopeful, but scrutiny may cast a shadow on the company’s future prospects